Management of dabigatran-induced anticoagulation in trauma and acute care surgery patients

Journal of Trauma and Acute Care Surgery

Volumn 73, Issue 5, 2012, Pages 1064-1069

  Obeng Gyasi, Samilia ^a   Loor, Michele M ^a   Samotowka, Michael A ^a   Moorman, Matthew L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN ETEXILATE; ENOXAPARIN; WARFARIN;

ACUTE APPENDICITIS; ADULT; AGED; ANTICOAGULATION; BLUNT TRAUMA; CASE REPORT; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EMERGENCY CARE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; MALE; PRIORITY JOURNAL; REVIEW; THORAX INJURY; THROMBIN TIME; VENOUS THROMBOEMBOLISM;

ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; HEMORRHAGE; HUMANS; WOUNDS AND INJURIES;

EID: 84869819592     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0b013e31827019c9     Document Type: Review

References (24)

1. Dossett LA, Riesel JN, GriffinMR, Cotton BA. Prevalence and implications of preinjury warfarin use. Arch Surg. 2011;146: 565-570.
2. Pieracci FM, Eachempatie SR, Shou J, Hydo LJ, Barie PS. Degree of anticoagulation, but not warfarin use itself, predicts adverse outcomes after traumatic brain injury in elderly trauma patients. J Trauma. 2007; 63: 525-530.
3. Dzik W. Reversal of drug-induced anticoagulation: old solutions and new problems. Transfusion. 2012;52:45SY55S.
4. Hauser CJ, Boffard K, Dutton R, Bernard GR, Croce MA, Holcomb JB, Leppaniemi A, Parr M, Vincent JL, Tortella BJ, et al. Results of the CONTROL Trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. J Trauma. 2010;69: 489-500.
5. Ma TKW, Yan BP, Lam YY. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice: a review of clinical data. Pharmacol Ther. 2011;129: 185-194.
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361: 1139-1151.
7. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361: 2342-2352.
8. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest. 2012;141(suppl 2):e44sYe88s.
9. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012;107: 985-997.
10. Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol. 2011;7: 281-287.
11. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate. Circulation. 2011;124: 1573-1579.
12. Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med. 2011;365: 2039-2040.
13. FDA Drug Safety Communication: Safety review of post-market reports of serious bleeding events with the anticoagulant Pradaxa (dabigatran etexilate mesylate). Available at: http://www.fda.gov/drugs/drugsafety/ucm282724.htm. Accessed 16 May 2012.
14. Garber ST, Sivakumar W, Schmidt RH. Neurosurgical complications of direct thrombin inhibitorsVcatastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg. 2012;116: 1093-1096.
15. Truumees E, Gaudu T, dieterichs C, Geck M, Stokes J. Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa [dabigatran]. Spine (Phila Pa 1976). 2012;37:E863-865.
16. Eisert WG, Hauel N, Stangier J, Wienen W. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol. 2010;30: 1885-1889.
17. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilateVa novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103: 1116-1127.
18. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47: 47-59.
19. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. An open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49: 259-268.
20. Pradaxa Medication Guide. Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT; April 2012. Available at: http://www.fda.gov/downloads/Drugs/ DrugSafety/UCM231720.pdf. Accessed 16 May 2012.
21. Stangier J, Feuring M. Using the hemoclot direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23: 138-143.
22. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants. antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(suppl 2):e24sYe43s.
23. Dabigatran (Pradaxa) Testing. Aniara Corporation. West Chester, OH. Available at: http://www.dabigatrantesting.com. Accessed 19 May 2012.
24. van Ryn J, Ruehl D, Priepke H, Hauel N. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIA or activated prothrombin complex concentrate. (Presented at the 13th Congress of the European Hematology Association) [abstract]. Haematologica. 2008;93: 148-0370.